National Institutes of Health (NIH) Funding

The Division of Hematology/Oncology has maintained a strong commitment to research. This investment has been rewarded with success in receiving both grant funding and clinical research opportunities.

National Cancer Institute (NCI) Funding

P30 NCI-designated comprehensive cancer center. The UPMC Hillman Cancer Center is one of only 51 NCI-designated comprehensive cancer centers in the country and the only one in Western Pennsylvania. These Cancer Centers of Excellence are recognized by the NCI for their scientific leadership, resources, and the depth and breadth of cancer research in basic, clinical, and/or population science. A large number of Division faculty play important roles in this P30 grant, including:

• Riyue Bao, PhD – Co-Director of Cancer Bioinformatics Services
• Adam Brufsky, MD, PhD – Co-Leader, Cancer Therapeutics Program
• Ronald J Buckanovich, MD, PhD – Co-Leader, Cancer Biology Program
• Leisha A Emens, MD, PhD – Co-Leader, Cancer Immunology and Immunotherapy Program
• James G Herman, MD – Co-Leader, Cancer Epidemiology and Prevention Program
• Yen-Michael Hsu, MD, PhD – Director, Immunologic Monitoring and Cellular Products Laboratory
• Linda B. Robertson, DPH, MSN, BSN – Associate Director, Health Equity and Community Outreach & Engagement
• John C. Schmitz, PhD – Co-Director, Cancer Pharmacokinetics and Pharmacodynamics Facility (CPPF)
• Hassane M. Zarour, MD – Co-Leader, Cancer Immunology and Immunotherapy Program
• Antoinette Wozniak, MD, – Associate Director of Clinical Research